Celldex phase 2 study of barzolvolimab in atopic dermatitis misses primary endpoint
FROM THE WIRE · GLOBENEWSWIRE.COM
HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishMissing the primary endpoint can weigh on expectations for the program and the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The phase 2 study of barzolvolimab in moderate to severe atopic dermatitis did not meet its primary endpoint.
- 02Key secondary endpoints were also not met.
- 03Observed improvements did not meet the company's internal hurdle rate for continued development.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets